SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS AND CARDIOVASCULAR EVENT PROTECTIONS: HOW APPLICABLE ARE CLINICAL TRIALS AND OBSERVATIONAL STUDIES TO REAL-WORLD PATIENTS?

Objective This study evaluated the characteristics of new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) in clinical practice click here to assess the applicability of the findings from clinical trials (Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, Dapagliflozin Effect on Cardiovascu

The in-place, or presential, economy has become the prime source of jobs in France’s highland areas.Yet little research has investigated this category of activity, which is also undervalued by economic players.Focusing primarily on production, classical economic analysis has minimized both the economic and social role of these sectors, and by ext

Abstract Background Doxorubicin (DOX) is an anthracycline agent mostly prescribed for various cancers.However, its treatment is contiguous with toxic effects.Acacia hydaspica prevented drug-induced hepatic-toxicity in animals with anti-oxidative mechanisms.We intended to study the efficacy of A.hydaspica ethyl acetate extract (AHE) for inhibiting D

One in seven Americans participates in the Supplemental Nutrition Assistance Program (SNAP), making it the largest federally funded food assistance program.SNAP benefits are distributed once per month and both food spending and calorie consumption tend to decrease as time from benefit distribution increases.The monthly SNAP benefit cycle has seriou